Ipamorelin
Fat LossSelective GHS / researchExperimental
Pentapeptide ghrelin-receptor agonist noted for GH release with relatively less ACTH/cortisol than older GHRPs. Not FDA-approved. WADA S2 (named).
For research use only.
Key Facts
- CAS
- 170851-70-4
- Molecular Weight (MW)
- 711.9 g/mol
- Half-life
- ~2 hours
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- 1–3× daily
- Last updated
- 8/23/2026
- Targets
- GHSR
Overview
Pentapeptide ghrelin-receptor agonist noted for GH release with relatively less ACTH/cortisol than older GHRPs. Not FDA-approved. WADA S2 (named).
Protocol
- Dosage Range
- 200–300 mcg per injection
- Frequency
- 1–3× daily
- Cycle
- 8–12 weeks on / 4 weeks off
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Add 2 mL bacteriostatic water per 5 mg vial.
Science
Mechanism of Action
Selective GHSR agonist; published human data show GH release with minimal cortisol/prolactin compared with GHRP-6 or hexarelin.
Targets
GHSR
Studies
- Ipamorelin selective GH secretagogue— Journal/year not available
Benefits
Cleaner GH-axis probe versus older GHRPs
Potential Side Effects
- Headache
- Flushing
- Water retention
References
- PMID 9849822External link · Year —
- WADA Prohibited List 2026External link · Year —